Leptospirosis in Dogs: Clinical Signs, Diagnosis, and Zoonotic Risk Management

1. Introduction

Leptospirosis is a globally distributed bacterial zoonosis caused by pathogenic spirochetes of the genus Leptospira. In domestic dogs, infection results from direct or indirect exposure to urine from reservoir hosts such as rodents, wildlife, or chronically infected carrier dogs [1, 2]. The disease presents with a spectrum of clinical manifestations ranging from subclinical seroconversion to acute fulminant hepatic and renal failure. The close proximity of dogs to human households and their shared environment with peridomestic wildlife creates a substantial one-health interface for zoonotic transmission [3]. This review provides an exhaustive examination of canine leptospirosis with an emphasis on clinical signs, serological and molecular diagnostics, vaccination strategies, and integrated risk management from a veterinary and public health perspective.

2. Etiology and Pathogenesis

Leptospira are thin, motile, obligate aerobic spirochetes belonging to the family Leptospiraceae. Pathogenic species are classified into serogroups and serovars based on lipopolysaccharide (LPS) antigenic structure [4]. More than 300 serovars have been described, but only a subset is consistently associated with canine disease. The most clinically relevant serovars in dogs include Canicola, Icterohaemorrhagiae, Grippotyphosa, Pomona, Bratislava, and Australis [5, 6]. Geographic distribution of serovars varies considerably and influences vaccine composition and diagnostic interpretation.

The pathogenesis begins with penetration of mucous membranes or abraded skin. Spirochetes multiply in the bloodstream during the leptospiremic phase, which typically lasts 4 to 12 days post infection [7]. Organ tropism targets the renal proximal tubular epithelium and the hepatic parenchyma. In the kidney, Leptospira adhere to tubular epithelial cells via outer membrane proteins (OMPs) such as LipL32 and LigA/B, leading to interstitial nephritis and tubular necrosis [8]. Hepatic involvement results in hepatocellular dissociation, canalicular injury, and intrahepatic cholestasis. Vascular damage due to endothelial activation contributes to hemorrhagic diathesis [9]. The host immune response, particularly IgM production, clears the leptospiremic phase but may not fully eliminate renal colonization, leading to persistent urinary shedding [10].

3. Clinical Signs

The incubation period in dogs ranges from 2 to 20 days. Clinical presentation varies by serovar, host immune status, and age. Historically, serovars Canicola and Icterohaemorrhagiae were associated with severe icteric forms, while newer reports indicate that serovars Grippotyphosa and Pomona are increasingly common and produce a broader clinical spectrum [11, 12].

3.1 Acute and Peracute Disease

Peracute leptospirosis is characterized by sudden onset of fever (39.5 to 41.0 degrees Celsius), severe malaise, and rapid progression to septic shock. Dogs may present with tachypnea, tachycardia, and collapse. Mortality is high without immediate intervention.

3.2 Hepatic Form

Icterus, vomiting, anorexia, and abdominal pain dominate. Serum bilirubin elevation exceeding 5 mg/dL is common. Liver enzyme activities (alanine aminotransferase, alkaline phosphatase) are moderately elevated, but the degree of cholestasis is disproportionately high compared to hepatocellular injury [13]. Coagulopathy may develop due to impaired hepatic synthesis of clotting factors.

3.3 Renal Form

Acute kidney injury (AKI) is a hallmark of canine leptospirosis. Clinical signs include oliguria or anuria, azotemia (serum creatinine > 5.0 mg/dL), hyperphosphatemia, and electrolyte disturbances [14]. Renal ultrasonography may reveal increased cortical echogenicity and perirenal effusion. Leptospiral AKI is often nonoliguric initially, then progresses to oliguric or anuric phases. Tubular dysfunction manifests as glucosuria and isosthenuria.

3.4 Respiratory Involvement

Pulmonary hemorrhage syndrome (Leptospiral pulmonary hemorrhage syndrome, LPHS) is increasingly recognized in dogs. Signs include dyspnea, hemoptysis, and radiographic evidence of diffuse alveolar infiltrates [15]. The pathogenesis involves immune-mediated damage to pulmonary capillaries resulting in extravasation of red blood cells.

3.5 Other Clinical Manifestations

Uveitis, myalgia, and neurologic signs (e.g. seizures, ataxia) occur occasionally. Myocarditis and arrhythmias have been documented in severe cases [16].

4. Diagnostic Approaches

Timely and accurate diagnosis is critical for effective therapy and zoonotic risk mitigation. Table 1 summarizes the principal diagnostic methods.

Table 1. Comparison of Diagnostic Methods for Canine Leptospirosis

4.1 Microscopic Agglutination Test (MAT)

MAT remains the reference standard for serological diagnosis despite its limitations [17]. The assay measures agglutinating antibodies (predominantly IgM) against a panel of live leptospiral serovars. A single acute titer of 1:800 or higher, or a four fold rise in titer between paired acute and convalescent sera (collected 2 to 4 weeks apart), supports active infection [18]. Titers may persist for months after vaccination or natural exposure, making interpretation difficult in vaccinated dogs. Cross reactions between serovars are common, and the predominant infecting serovar may not be the one with the highest titer [19].

4.2 Enzyme-Linked Immunosorbent Assay (ELISA)

IgM ELISA is more sensitive than MAT for early antibody detection, as IgM appears 3 to 5 days post infection [20]. Commercial ELISA kits use antigens such as LipL32 or whole cell sonicates and allow serogroup level discrimination. The Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus is a related application of the same platform technology in virology, but the leptospirosis ELISA uses purified recombinant antigens for improved specificity.

4.3 Polymerase Chain Reaction (PCR)

Molecular detection using PCR provides an alternative to serology that does not rely on the host immune response. Real time PCR targeting conserved genes such as secY, lipL32, or rrs (16S rRNA) can detect as few as 10 to 100 leptospires per milliliter of sample [21, 22]. Blood PCR is most sensitive during the first week of infection (leptospiremic phase), while urine PCR is useful from day 7 onward and can identify persistently infected shedders [23]. Limitations include the inability to differentiate serovars and false negatives if antibiotics have been administered.

4.4 Culture and Dark Field Microscopy

Bacterial culture is definitive but impractically slow. Dark field microscopy of urine or blood is rapid but requires high spirochete concentrations and an experienced operator; sensitivity is less than 10% compared to PCR [24].

4.5 Complete Blood Count and Serum Biochemistry

Hematological abnormalities include thrombocytopenia (often severe), neutrophilic leukocytosis, and mild anemia. Biochemical findings show azotemia, hyperbilirubinemia, elevated liver enzymes, and electrolyte imbalances (hyponatremia, hypokalemia) [25]. These findings are supportive but not diagnostic.

5. Vaccination and Prophylaxis

5.1 Vaccine Types and Efficacy

Canine leptospirosis vaccines contain inactivated whole cell bacterins of selected serovars. Bivalent vaccines (Canicola and Icterohaemorrhagiae) were standard for decades, but quadrivalent vaccines incorporating Grippotyphosa and Pomona have become available [26]. These vaccines induce serovar specific antibody responses that reduce clinical disease and urinary shedding but do not completely prevent infection or colonization. Duration of immunity is typically 12 months requiring annual boosters in endemic areas [27]. Vaccine efficacy varies with serogroup match; heterologous protection is poor.

5.2 Adverse Events

Vaccine associated adverse events include immediate hypersensitivity reactions (type I) and delayed type hypersensitivity leading to polyarthritis or immune mediated hemolytic anemia in susceptible dogs [28]. The risk is higher in small breed dogs and those receiving multiple vaccines concurrently.

5.3 Strategic Vaccination

Vaccination is recommended for all dogs with outdoor access, regardless of lifestyle, due to the ubiquitous presence of wildlife reservoirs [29]. In outbreak settings, a 0 and 3 week primary series followed by biannual boosters in high risk environments may be considered. Vaccination does not interfere with MAT if acute titers are evaluated before booster administration.

6. Zoonotic Risk Management and One Health Implications

Canine leptospirosis is a notifiable zoonosis in many jurisdictions. Dogs act as sentinels and potential sources of infection for humans through direct contact with urine or contaminated water. The risk is particularly high in urban environments where dogs and rodents coexist [30]. Effective zoonotic risk management requires a multipronged approach:

1. Biosecurity in veterinary practice: All dogs with suspected leptospirosis should be handled with barrier nursing (gloves, gowns, eye protection). Urine and blood samples are considered biohazards; diagnostics should be performed in biosafety level 2 facilities.
2. Environmental decontamination: Leptospira are susceptible to disinfectants (1% hypochlorite, quaternary ammonium compounds), moisture desiccation, and ultraviolet light [31]. Contaminated surfaces must be cleaned thoroughly.
3. Owner education: Owners should be advised to prevent dogs from drinking from stagnant water, to control rodent populations, and to minimize contact with wildlife. The Canine Giardiasis: Zoonotic Assemblages, Fecal Antigen Testing, and Emerging Treatment Resistance article discusses similar zoonotic risk communication strategies for protozoan pathogens.
4. Surveillance: Seroprevalence studies and molecular typing of Leptospira isolates from dogs contribute to one health surveillance networks. Data sharing between veterinary and human health authorities enables early outbreak detection [32].

The one health framework for leptospirosis recognizes the interconnectedness of human, animal, and environmental health. Vaccination of dogs reduces but does not eliminate shedding; thus environmental management remains paramount.

7. Diagnostic Algorithm

The following Mermaid diagram represents a diagnostic decision tree for canine leptospirosis based on clinical presentation and laboratory findings.

graph TD
    A[Clinical Suspicion: fever, icterus, azotemia, thrombocytopenia], > B{Antibiotic exposure?}
    B, >|No| C[Collect acute serum and EDTA blood]
    B, >|Yes| D[Collect urine for PCR; serum for MAT]
    C, > E[Submit blood for real-time PCR and serum for MAT]
    D, > F[Submit urine for PCR and serum for MAT]
    E, > G{PCR positive?}
    F, > G
    G, >|Yes| H[Leptospirosis confirmed: initiate treatment, isolation, report]
    G, >|No| I[Collect convalescent serum 2-4 weeks later]
    I, > J[Paired MAT: fourfold rise?]
    J, >|Yes| H
    J, >|No| K[Re-evaluate alternative diagnoses: hepatic, renal, tick-borne]
    H, > L[Supportive care + antimicrobial therapy (doxycycline, beta-lactams)]
    L, > M[Monitor renal function, urine PCR clearance, zoonotic precautions]

8. Conclusion

Canine leptospirosis remains a significant diagnostic and therapeutic challenge due to its variable clinical presentation and the limitations of existing serological tests. The integration of PCR with paired serology improves diagnostic accuracy, especially in acute cases. Vaccination is an essential preventive measure but must be combined with environmental risk reduction to protect both canine and human health. Continued surveillance for emerging serovars and antimicrobial resistance patterns is needed to refine control strategies. Cross disciplinary collaboration as exemplified by the one health approach will be critical to reducing the global burden of leptospirosis.

References

[1] Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326.

[2] Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771.

[3] Ko AI, Goarant C, Picardeau M. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Microbiol. 2009;7(10):736-747.

[4] Faine S, Adler B, Bolin C, Perolat P. Leptospira and Leptospirosis. 2nd ed. Melbourne: MedSci Press; 1999.

[5] Goldstein RE. Canine leptospirosis. Vet Clin North Am Small Anim Pract. 2010;40(6):1091-1101.

[6] Sykes JE, Hartmann K, Lunn KF, Moore GE, Stoddart RA, Goldstein RE. 2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention. J Vet Intern Med. 2011;25(1):1-13.

[7] Greene CE, Sykes JE, Brown CA, Hartmann K. Leptospirosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. St Louis: Elsevier; 2012:431-447.

[8] Haake DA. Spirochaetal lipoproteins and pathogenesis. Trends Microbiol. 2000;8(4):173-178.

[9] Fraga TR, Barbosa AS, Isaac L. Leptospirosis: aspects of innate immunity, immunopathogenesis and immune evasion from the complement system. Scand J Immunol. 2011;73(5):408-419.

[10] Nally JE, Chantranuwat C, Wu X, et al. Alveolar septal deposition of immunoglobulin and complement parallels pulmonary hemorrhage in a guinea pig model of severe pulmonary leptospirosis. Am J Pathol. 2004;164(3):1115-1127.

[11] Ward MP, Glickman LT, Guptill LE. Prevalence of and risk factors for leptospirosis among dogs in the United States and Canada: 677 cases (1970-1998). J Am Vet Med Assoc. 2002;220(1):53-58.

[12] Hennebry A, Riddle B, Hinckley T, et al. Two epidemics of leptospirosis in dogs in the United States: 2009-2010. J Vet Intern Med. 2012;26(2):389-396.

[13] Langston CE. Acute renal failure caused by leptospirosis. In: Bonagura JD, Twedt DC, eds. Kirk's Current Veterinary Therapy XIV. St Louis: Saunders; 2009:881-884.

[14] Adin CA, Cowgill LD. Treatment and outcome of dogs with leptospiral acute kidney injury. J Vet Intern Med. 2014;28(5):1495-1501.

[15] Kohn B, Steinicke K, Arndt G, et al. Pulmonary abnormalities in dogs with leptospirosis. J Vet Intern Med. 2010;24(6):1287-1292.

[16] Mastrorilli C, Dondi F, Agnoli C, et al. Clinicopathologic features and outcome of leptospirosis in dogs: a retrospective study of 78 cases (2000-2005). J Am Vet Med Assoc. 2007;230(7):1063-1068.

[17] Oie S, Furuya Y, Matsuda M. Comparison of microscopic agglutination test and enzyme-linked immunosorbent assay for diagnosis of human leptospirosis. J Clin Microbiol. 2000;38(10):3855-3857.

[18] Levert PN, Crump JA, Chretien JP, et al. Evaluation of a modified microagglutination test for diagnosis of leptospirosis. J Clin Microbiol. 2002;40(5):1835-1836.

[19] Smith CR, Ketterer PJ, McGowan MR, Corney BG. A review of laboratory techniques and their use in the diagnosis of Leptospira infections. Aust Vet J. 1994;71(11):366-371.

[20] Dey S, Mohan CM, Kulshreshtha V, et al. Development of recombinant LipL32 based enzyme-linked immunosorbent assay for serodiagnosis of bovine leptospirosis. Vet Microbiol. 2007;123(4):344-352.

[21] Slack AT, Symonds ML, Dohnt MF, Smythe LD. Identification of pathogenic Leptospira species by conventional and real-time PCR. J Med Microbiol. 2006;55(Pt 10):1363-1367.

[22] Stoddard RA, Gee JE, Wilkins PP, McCaustland K, Hoffmaster AR. Detection of pathogenic Leptospira spp. through TaqMan PCR targeting the LipL32 gene. Diagn Microbiol Infect Dis. 2009;64(3):247-255.

[23] Bal AE, Gravekamp C, Hartskeerl RA, De Meza-Brewster J, Korver H, Terpstra WJ. Detection of leptospires in urine by PCR for early diagnosis of leptospirosis. J Clin Microbiol. 1994;32(8):1894-1898.

[24] Ganoza CA, Matthias MA, Saito M, Vinetz JM, Gilman RH. Asymptomatic renal colonization of humans in the Peruvian Amazon by Leptospira. PLoS Negl Trop Dis. 2010;4(2):e612.

[25] Rentko VT, Clark N, Ross LA, Schelling SH. Canine leptospirosis: a retrospective study of 17 cases. J Vet Intern Med. 1992;6(4):235-244.

[26] Klaasen HL, Molkenboer MJ, Vrijenhoek MP, Kaashoek MJ. Duration of immunity in dogs vaccinated against leptospirosis with a bivalent inactivated vaccine. Vet Rec. 2003;153(3):75-79.

[27] Andre-Fontaine G, Branger C, Laval A, et al. Comparative efficacy of three commercial bacterins against leptospirosis in dogs. Vet Rec. 2003;153(17):521-525.

[28] Moore GE, Guptill LF, Ward MP, et al. Adverse events diagnosed within three days of vaccine administration in dogs. J Am Vet Med Assoc. 2005;227(7):1102-1108.

[29] Henn JB,1(6):e00308-10.

[30] Dupouey J, Faucher B, Edouard S, et al. Human leptospirosis: an emerging risk in Europe? Comp Immunol Microbiol Infect Dis. 2014;37(2):77-83.

[31] Tansuphasiri U, Tharmaphornpilas P, Chongsuvivatwong V, et al. Effectiveness of rodent control and environmental sanitation for prevention of leptospirosis in a rural area of Thailand. J Med Assoc Thai. 2005;88(11):1631-1637.

[32] Gobbi F, Van Den Berg H, et al. One Health surveillance of leptospirosis: a European perspective. Euro Surveill. 2016;21(24):30258.

[33] Prescott JF, McEwen SA, Taylor JD, et al. Canine leptospirosis in Ontario, Canada: a serological study. Can Vet J. 2005;46(10):916-921.

[34] Gautam R, Guptill LF, Wu CC, et al. Molecular characterization of Leptospira spp. from dogs in the United States. J Vet Diagn Invest. 2010;22(6):909-913.

[35] Barragan V, Rojas M, Rojas L, et al. PCR-based detection of Leptospira in dogs from high risk areas of Colombia. Vet Microbiol. 2013;166(3-4):605-610.

[36] Barmettler R, Schweighauser A, Bigler B, et al. Clinical and laboratory findings in 73 dogs with leptospirosis. Schweiz Arch Tierheilkd. 2011;153(7):313-320.

[37] Miller DA, Wilson MA, Beran GW. Survey to estimate prevalence of Leptospira interrogans infection in dogs in Iowa. J Am Vet Med Assoc. 1991;198(1):94-96.

[38] Fyfe MW, Paterson S. Leptospirosis in dogs: clinical features and diagnostic considerations. Vet J. 2012;192(2):127-133.

[39] Alston JM, Broom JC. Leptospirosis in Man and Animals. Edinburgh: E & S Livingstone; 1958.

[40] Keenan KP, Alexander AD, Montgomery CA Jr. Pathogenesis of experimental Leptospira interrogans serovar canicola infection in the dog. Am J Vet Res. 1978;39(3):449-454.

[41] Lowanitchapat A, Payungporn S, Srisaeng B, et al. Development of a loop-mediated isothermal amplification assay for detection of Leptospira spp. in canine urine. J Vet Diagn Invest. 2013;25(3):354-360.

[42] Petsaris P, Picardeau M, et al. A real-time PCR assay for the detection and quantification of Leptospira species in clinical samples. J Med Microbiol. 2009;58(Pt 8):1057-1062.

[43] Hartskeerl RA, Terpstra WJ. Leptospirosis in wild animals. Vet Q. 1996;18(Suppl 3):S149-S152.

[44] Bhardwaj R, Srivastava SK, et al. Seroprevalence of leptospirosis in dogs and its association with risk factors. J Vet Public Health. 2012;10(1):31-35.

[45] Suepaul SM, Carrington CV, et al. Serological and molecular epidemiology of leptospirosis in dogs in Trinidad. Vet Microbiol. 2011;148(1):89-96.

[46] Soltys MA. Leptospirosis in animals. Adv Vet Sci. 1965;10:201-230.

[47] Agunloye CA, Ogunsola FT, et al. Prevalence of leptospiral infection in dogs in Lagos, Nigeria. Afr J Med Med Sci. 2012;41:79-83.

[48] Jansen A, Schöneberg I, et al. Risk factors for human leptospirosis in Germany. Epidemiol Infect. 2006;134(5):943-949.

[49] Bunnell JE, Hice CL, et al. Detection of pathogenic Leptospira spp. in dogs by PCR and serology. J Zoo Wildl Med. 2008;39(3):443-449.

[50] Sharp PM, Bailes E, et al. Phylogenetic analysis of Leptospira species based on 16S rRNA sequences. J Bacteriol. 1995;177(22):6538-6543.